sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Valacyclovir

Medicine

Valacyclovir

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome.; Acute Renal Failure.; Central Nervous System Effects.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome.; Acute Renal Failure.; Central Nervous System Effects.

Side effects, and when to stop

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

  • Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome.
  • Acute Renal Failure.
  • Central Nervous System Effects.
  • Severe Cutaneous Adverse Reactions.

The most common adverse reactions reported in at least 1 indication by greater than 10% of adult subjects treated with valacyclovir tablets and observed more frequently with valacyclovir tablets compared with placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in greater than 10% of pediatric subjects aged less than 18 years was headache.

Who should not take it

Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction [e.g., anaphylaxis, severe cutaneous adverse reactions (SCARs)] to valacyclovir, acyclovir, or any component of the formulation.

Other medicines and interactions

No clinically significant drug-drug or drug-food interactions with valacyclovir tablets are known.

2 dosage and administration

  • Valacyclovir tablets may be given without regard to meals.
  • Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Valacyclovir; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/valacyclovir

APA 7th

sofidex. (2026, August 3). Valacyclovir. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/valacyclovir

AMA 11th

Valacyclovir. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/valacyclovir

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.